What Happened

Revelation Biosciences reported its financial results for Q2 and H1 2026, emphasizing progress in its Phase 2/3 clinical study for Gemini in acute kidney injury (AKI). The company formed an AKI Advisory Board and identified a $94 billion total addressable market for Gemini.

Who Is Affected

Key stakeholders include healthcare providers focused on AKI treatment, investors in clinical-stage biotech companies, and pharmaceutical firms interested in innovative inflammation therapies.

Market Impact

• Potential $94 billion market for Gemini in AKI treatment.
• Increased interest from advisory boards and investors.
• Opportunities for partnerships in chronic kidney disease and post-surgical infection treatments.

What to Watch

Monitor Revelation's progress in enrolling patients for its Phase 2/3 AKI clinical trial by year-end 2026. Also, watch for updates on Gemini's applications in chronic kidney disease and severe burn treatments.

Related coverage

• Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes